Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vortioxetine for Depression in Parkinson's Disease
NCT04301492Phase 4Unknown
- Sponsor
- Fondazione San Raffaele Monte Tabor
- Start
- Nov 2019
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of vortioxetine in major depressive disorder (MDD), sponsored by Fondazione San Raffaele Monte Tabor. Status: unknown.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04301492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04301492.